Róisín Shortall (Dublin North West, Social Democrats)
Link to this: Individually | In context | Oireachtas source

284. To ask the Minister for Health his plans to make orally inhaled levodopa (details supplied) available under the long-term illness scheme to treat Parkinson’s symptoms; and if he will make a statement on the matter. [21038/23]

Stephen Donnelly (Wicklow, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

The Health Service Executive (HSE) has statutory responsibility medicine pricing and reimbursement decisions, in accordance with the provisions of the Health (Pricing and Supply of Medical Goods) Act 2013.

Reimbursement is for licensed indications which have been granted market authorisation by the European Medicines Agency (EMA) or the Health Products Regulatory Authority (HPRA).

In line with the 2013 Act and the national framework agreed with industry, a company must submit an application to the HSE to have a new medicine added to the reimbursement list.

The HSE has not, to date, received a pricing and reimbursement application for Inbrija® (levodopa) inhalation powder capsules.

Therefore, reimbursement support for Inbrija® is not available under any community drug schemes, including the Long Term Illness Scheme.